CHRS — STC-15 Clinical Trial Completion
Jan 29, 2026, 5:00:00 AM UTC
Summary
The clinical trial investigating STC-15, a METTL3 inhibitor, in combination with toripalimab, an anti-PD-1 therapy, is expected to complete on January 29, 2026. This early-phase oncology trial focuses on advanced cancers, including non-small cell lung cancer, melanoma, endometrial cancers, and head and neck squamous cell carcinoma. Conducted at various study centers, the trial aims to assess the safety, tolerability, and antitumor activity of the combination treatment.
Company
COHERUS BIOSCIENCES INC (CHRS)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.coherus.comSimilar Events
Expected Trial Completion for TST001 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics is expected to complete a Phase 1/2 clinical trial of TST001 in advanced or metastatic solid tumors on September 30, 2025. The study evaluates the safety and tolerability of TST001, a CLDN18.2-targeting monoclonal antibody, in combination with standard therapies across multiple cohorts, including gastric, gastroesophageal junction, and pancreatic cancers. The trial's completion will provide key data for further development and potential regulatory submissions.
trial completionClinical Trial Completion for Tislelizumab in Cancer Patients
The clinical trial for tislelizumab, focusing on patients with molecular residual disease (MRD), is set to complete on April 1, 2030. This Phase 3 trial aims to evaluate the efficacy of tislelizumab monotherapy in early-stage cancer treatment, particularly for patients identified with MRD+ status. The trial is being conducted at Gustave Roussy, Cancer Campus, Grand Paris, and involves 717 participants. The study seeks to enhance early detection and monitoring of cancer recurrence through advanced detection of circulating tumor DNA.
trial completionExpected Trial Completion for Tisotumab Vedotin Study
A Phase 2 clinical trial evaluating tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in patients with selected solid tumors is expected to complete on August 14, 2026. The study, sponsored by Seagen (a Pfizer subsidiary) and involving Genmab (GMAB), is assessing efficacy, safety, and tolerability in tumor types including colorectal cancer, squamous non-small cell lung cancer, exocrine pancreatic adenocarcinoma, and head and neck squamous cell carcinoma. The trial has enrolled 352 participants and is not currently recruiting.
trial completionClinical Trial Completion for Toripalimab in Recurrent Metastatic Nasopharyngeal Cancer
Coherus Biosciences is conducting a Phase 4 clinical trial evaluating toripalimab, an anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for first-line treatment of recurrent metastatic nasopharyngeal cancer. The study aims to assess efficacy based on objective response rate, with trial completion expected by December 1, 2027. Toripalimab is an immunotherapy product targeting PD-1, used in oncology for various solid tumors.
trial completion